BioVie and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NYSE - LSE

CMSC	0.35%	22.91	$
RBGPF	-6.25%	64.94	$
VOD	1.98%	15.62	$
RYCEF	2.83%	15.54	$
AZN	-1.26%	192.38	$
RIO	-1.44%	98.86	$
RELX	-0.4%	36.125	$
NGG	1.59%	86.985	$
BTI	1.95%	57.29	$
GSK	-0.15%	55.615	$
CMSD	0.39%	23.22	$
BCE	1.49%	24.09	$
BCC	1.87%	83.805	$
JRI	-0.85%	12.89	$
BP	-0.05%	46.345	$

BioVie and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ECONOMY 26.09.2025

ORLANDO, FLORIDA / ACCESS Newswire / September 26, 2025 / RedChip Companies will air interviews with BioVie Inc. (NASDAQ:BIVI) and FibroBiologics, Inc. (Nasdaq:FBLG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, September 27, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

Text size:

Access the interviews in their entirety at:

In an exclusive interview, Cuong Do, President and CEO of BioVie, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss bezisterim (NE3107), BioVie's first-in-class, orally available small molecule that targets inflammation and insulin resistance, two key drivers of Alzheimer's, Parkinson's, and Long COVID, where it has shown encouraging signals of improved cognition, motor function, and reduced neuroinflammation across clinical studies. He will also outline progress with BIV201, BioVie's late-stage orphan drug candidate for refractory ascites, a life-threatening complication of liver cirrhosis with no FDA-approved therapies. With multiple late-stage clinical programs advancing, strong safety data, and multi-billion-dollar market opportunities, BioVie is positioned to deliver significant value creation as it approaches pivotal milestones and potential partnerships.

Pete O'Heeron, CEO of FibroBiologics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to spotlight the company's pioneering work in fibroblast-based cell therapies. O'Heeron discusses the advantages of fibroblasts over traditional stem cells, highlighting their regenerative and immunomodulatory properties, scalability, and safety profile. He outlines the Company's robust pipeline, led by CYWC628 for diabetic foot ulcers, which is slated to enter a Phase 1/2 clinical trial in Australia later this year. Additional programs, including CybroCell™ for degenerative disc disease and CYMS101 for multiple sclerosis, target multi-billion-dollar markets and are supported by promising preclinical and early human data. With over 240 issued and pending patents, a recently completed cGMP-compliant cell bank, and a seasoned leadership team, FibroBiologics is advancing a scalable, off-the-shelf platform poised to transform treatment for chronic diseases and deliver significant long-term value to shareholders.

BIVI and FBLG are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.

About BioVie, Inc.

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer's disease, Parkinson's disease and long COVID) and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-κB, and the associated neuroinflammation and insulin resistance but not ERK and NFκB homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of AD and PD. Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit www.bioviepharma.com.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

About RedChip Companies

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.

To learn more about RedChip's products and services, please visit:

https://www.redchip.com/corporate/investor_relations

"Discovering Tomorrow's Blue Chips Today"™

Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

Follow RedChip on Twitter: https://twitter.com/RedChip

Follow RedChip on YouTube: https://www.youtube.com/@redchip

Follow RedChip on Rumble: https://rumble.com/c/c-3068340

Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

Contact:

Dave Gentry
RedChip Companies Inc.
1-407-644-4256
[email protected]